SynCore Bio is selected to present the Phase I study data of new anti-cancer molecule SB01 at ASCO 2017
SynCore Biotechnology Co., Ltd. (SynCore) received the official notification stating the selection for presentation of SB01 Phase I study data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract was reviewed by the Scientific Program Committee and ASCO Leadership before being selected from more than 5,700 abstracts. ASCO is the largest and most representative global Oncology conference, an acclaimed platform for companies to present new drugs, as well as seek international collaboration opportunities.
SB01 is a novel anti-microtubular agent with vascular disrupting activity. Currently, the Phase II clinical trial is conducted on patients with squamous cell carcinoma of head and neck, under the investigational new drug (IND) approved by both US FDA and TFDA.
Dr. Muh-Hwan Su, General Manager, SynCore Biotechnology Co., Ltd, indicated that SB01 is the first anti-cancer new chemical entity (NCE) discovered in Taiwan, co-developed by SynCore, government and academic institutes subsequently. SynCore is honored to present the exciting clinical results at ASCO, on behalf of the whole Taiwan development team.
The 2017 ASCO Annual Meeting will take place at the McCormick Place Convention Center in Chicago, Illinois June 2-6, 2017.
The contents of the abstract will be released by ASCO May 17, 2017, at 5:00 PM EDT on abstracts.asco.org.
Abstract Title: A Phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy
Abstract Number: 2531